Salem, NH, June 17, 2010 --(
PR.com)--
BioPorto Diagnostics has awarded
ALPCO Diagnostics exclusive distributorship for its animal NGAL ELISAs to the North American market. BioPorto’s prominence is unrivaled in immunoassays for measuring NGAL (neutrophil gelatinase associated lipocalin) – the breakthrough kidney injury marker that was brought to market first by BioPorto. In Europe, NGAL is used to diagnose Acute Kidney Injury (AKI) within a few hours after an AKI causing event has occurred – a vast improvement over all other methods used to date. The availability of these assays can translate into considerable improvements in toxicity testing for the medical and drug industry in North America.
Sean Conley, President of ALPCO Diagnostics is excited about BioPorto’s NGAL Assays: “We are very pleased to offer the BioPorto NGAL products to the North American life science research markets. BioPorto has a proven reputation for producing high quality immunoassay products and offers the most comprehensive NGAL product range including
Canine NGAL ELISA,
Mouse NGAL ELISA, and
Rat NGAL ELISA with
Porcine NGAL ELISA and
Monkey NGAL ELISA launching soon.”
“ALPCO is a well established and reputable company in the life sciences industry and we are very pleased to have the opportunity to work together. A primary focus will be the promotion of our animal NGAL product line aimed at the pharmaceutical industry – ALPCO’s renowned competencies in this area coupled with the unmatched depth of our NGAL portfolio is a winning combination” says Thea Olesen, CEO, BioPorto Diagnostics.
For more information, visit
www.NGAL.com. Alternatively BioPorto will be presenting scientific posters at the upcoming
World Pharmaceutical Congress on some of latest breakthroughs with these assays while ALPCO will be available at booth #18 in the exhibitor area.
About ALPCO Diagnostics
Founded in 1990,
ALPCO Diagnostics is an importer and distributor of high quality research immunoassay kits. The company's goals then, as now, have been to offer a diverse line of assays that appeal to its broad customer base while providing exceptional customer service and product support. In recent years, ALPCO has solidified its place in the market not only as a distributor but as a developer and manufacturer of immunoassays as well.
About BioPorto Diagnostics
BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. BioPorto’s developments include tests to diagnose and monitor acute kidney damage in humans and for basic research in animals. BioPorto’s strategy is to develop new methods based on its antibody portfolio that can be patented or have other competitive advantages and achieve a wide use in the diagnosis of various diseases. BioPorto is a Danish company founded in 2000 and listed on the NASDAQ OMX in Copenhagen.
###
